Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of 4-AP on Functional SCI Recovery
Sponsor: Shirley Ryan AbilityLab
Summary
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
Official title: Effects of 4-AP on Functional Recovery After Spinal Cord Injury
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
26
Start Date
2022-06-30
Completion Date
2025-06-30
Last Updated
2026-06-03
Healthy Volunteers
No
Conditions
Interventions
Dalfampridine
The study drug (4-AP) will be administered as a 10 mg dose.
Placebo drug
The pharmacy will also provide a placebo drug that looks identical to 4-AP to verify participants and therapists do not know who is receiving the drug and who is receiving the placebo.
STDP stimulation
Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
Exercise training
Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
Locations (1)
Shirley Ryan Abilitylab
Chicago, Illinois, United States